
Does cross-reactive immunity against seasonal HCoVs and SARS-CoV-2 reduce the severity of COVID-19?



Fusion peptide

S-OC43

Antibody titers in COVID-19 hospitalized patients

Conclusion Immunity against OC43 HCoV is successfully measured by anti-S-OC43 ELISA.

Anti-S-OC43 is an indicator of good prognosis in patients hospitalized with COVID-19.